

Michigan Office of Administrative Hearings and Rules

Administrative Rules Division (ARD)

MOAHR-Rules@michigan.gov

**REGULATORY IMPACT STATEMENT
and COST-BENEFIT ANALYSIS (RIS)**

Agency Information:

Department name:

Licensing and Regulatory Affairs

Bureau name:

Bureau of Professional Licensing

Name of person filling out RIS:

Andria Ditschman

Phone number of person filling out RIS:

517-290-3361

E-mail of person filling out RIS:

DitschmanA@michigan.gov

Rule Set Information:

ARD assigned rule set number:

2022-62 LR

Title of proposed rule set:

Pharmacy – Program for Utilization of Unused Prescription Drugs

Comparison of Rule(s) to Federal/State/Association Standard

1. Compare the proposed rules to parallel federal rules or standards set by a state or national licensing agency or accreditation association, if any exist.

Each state establishes its own requirements with respect to the utilization and destruction of unused prescription drugs.

The subject matter of these rules is contained in sections 17775 and 17776 of the Public Health Code (Code), MCL 333.17775 and 333.17776.

The purpose of the Pharmacy – Program for Utilization of Unused Prescription Drugs rules is to establish, implement, and administer a voluntary statewide unused prescription drug repository and distribution program consistent with the public health and safety, where unused or donated prescription drugs, other than controlled substances, may be transferred from a medical institution or manufacturer to a pharmacy or a charitable clinic that elects to participate in the program. In addition, the rules allow for controlled substances, as permitted by federal law, or prescriptions that are ineligible for distribution, to be accepted by participants in the program to be destroyed.

There are no federal standards related to the donation of non-controlled substance prescription drugs. However, there are federal standards for the collection and disposal of controlled substances. Specifically, the Secure and Responsible Drug Disposal Act of 2010 (Public Law 111-273, 124 Stat. 2858), grants the United States Attorney General authority to promulgate regulations that allow patients to deliver unused controlled substance prescriptions to appropriate entities for disposal in a safe and effective manner consistent with effective controls against diversion. The Drug Enforcement Administration's (DEA) rule, 21 CFR 1317, effective in 2014, expanded the options available to collect unused controlled substances for destruction, in addition to just discarding the drugs into the general waste stream or flushing the substances. The regulations allow for take-back events, mail-back programs, and collection receptacles. The proposed rules are consistent with the DEA regulations.

Under the Controlled Substances Act, (CSA), 21 USC 801 et seq., the federal government regulates the practice of pharmacy with respect to controlled substances and chemicals used in the manufacture of controlled substances and requires pharmacies to register or self-certify with the DEA. Registration with the DEA is required to prevent diversion and abuse of controlled substances and chemicals used in the manufacture of controlled substances, and to ensure an adequate and uninterrupted supply of controlled substances for the United States. A pharmacy must maintain a state license to get a DEA license.

Taking into consideration the federal laws and regulations referenced above, each state establishes its own requirements with respect to the utilization and destruction of unused prescription drugs.

A. Are these rules required by state law or federal mandate?

The proposed rules are required by section 17775(12) and 17776 of the Code, MCL 333.17775, 333.17776. The rules are not federally mandated.

B. If these rules exceed a federal standard, please identify the federal standard or citation, describe why it is necessary that the proposed rules exceed the federal standard or law, and specify the costs and benefits arising out of the deviation.

The proposed rules do not exceed a federal standard.

2. Compare the proposed rules to standards in similarly situated states, based on geographic location, topography, natural resources, commonalities, or economic similarities.

Each state establishes its own requirements with respect to the utilization and destruction of unused prescription drugs.

Many states have enacted laws for drug donation and reuse or destruction. All states in the Great Lakes region have enacted drug donation and reuse or a destruction program, however not all states have operational programs. Indiana allows donation on a limited basis. Minnesota's board of pharmacy has a medication drug repository program where donors may donate a drug or medical supply for use by an individual who meets specific eligibility criteria. Some states, such as Pennsylvania, limit their program to cancer drugs only.

A. If the rules exceed standards in those states, please explain why and specify the costs and benefits arising out of the deviation.

The proposed rules do not exceed standards in other states in the Great Lakes region. The proposed rules are required by sections 17775 and 17776 of the Code, MCL 333.17775, 333.17776, and participation is voluntary.

3. Identify any laws, rules, and other legal requirements that may duplicate, overlap, or conflict with the proposed rules.

As discussed in Question #1, sections 17775 and 17776 of the Code, MCL 333.17775, 333.17776, require rules to create an unused prescription repository, distribution, and destruction program.

Section 17775 of the Code, MCL 333.17775, expressly addresses any conflict which may arise with Michigan's cancer drug repository program established under section 17780 of the Code, MCL 333.177780, by stating that in the event of conflict, section 17780 of the Code, MCL 333.177780, controls.

The proposed rules are consistent with the DEA's regulations in 21 CFR Part 1317, effective in 2014, which expanded the options available to collect unused controlled substances, in addition to discarding or flushing the substances, by allowing for take-back events, mail-back programs, and collection receptacles.

A. Explain how the rules have been coordinated, to the extent practicable, with other federal, state, and local laws applicable to the same activity or subject matter. This section should include a discussion of the efforts undertaken by the agency to avoid or minimize duplication.

As a result of the Michigan board of pharmacy (board) rules committee work group process with the public, and research regarding federal laws and regulations, the resulting proposed rules are not in conflict with, and are consistent with, the Secure and Responsible Drug Disposal Act of 2010 and the DEA's regulations in 21 CFR Part 1317.

4. If MCL 24.232(8) applies and the proposed rules are more stringent than the applicable federally mandated standard, provide a statement of specific facts that establish the clear and convincing need to adopt the more stringent rules.

The federal government has not mandated that the state promulgate the proposed rules, consequently, MCL 24.232(8) is not applicable.

5. If MCL 24.232(9) applies and the proposed rules are more stringent than the applicable federal standard, provide either the Michigan statute that specifically authorizes the more stringent rules OR a statement of the specific facts that establish the clear and convincing need to adopt the more stringent rules.

The federal government has not mandated that the state promulgate rules, and the proposed rules are not more stringent than applicable federal standards. The proposed rules are not in conflict with and are consistent with the Secure and Responsible Drug Disposal Act of 2010 and the DEA's regulations in 21 CFR Part 1317.

Purpose and Objectives of the Rule(s)

6. Identify the behavior and frequency of behavior that the proposed rules are designed to alter.

The rules allow for re-distribution of prescription drug medication, whose integrity has been maintained in a closed system, to patients who may not otherwise be able to afford the medication. Secondly, the rules set standards for the destruction of prescription medication received from individuals that is not eligible for re-distribution. The rules allow for safe and environmentally conscious destruction of medications. They prevent diversion, and the use of expired medications. The proposed changes to the rules are designed to provide updates; increase the use of the program by pharmacies, charitable clinics, manufacturers, medical institutions, and individuals; and reduce the complexity and type of forms necessary to participate in the program.

A. Estimate the change in the frequency of the targeted behavior expected from the proposed rules.

The proposed rules are expected to alter the frequency of the targeted behavior by increasing the use of the program and reducing the complexity and type of forms necessary to participate in the program.

B. Describe the difference between current behavior/practice and desired behavior/practice.

The difference between current behavior and desired behavior is that more pharmacies, charitable clinics, medical institutions, manufacturers, and individuals will use the program, and those using the program will have an easier time filling out and maintaining forms.

C. What is the desired outcome?

The rules serve a two-fold purpose. The rules allow for re-distribution of prescription drug medication, whose integrity has been maintained in a closed system, to patients who may not otherwise be able to afford the medication. Secondly, the rules set standards for the destruction of prescription medication received from individuals that is not eligible for re-distribution. The rules provide for the safe and environmentally conscious destruction of medications and prevent diversion, overdoses, and the use of expired medications. The desired outcome is that more pharmacies, charitable clinics, medical institutions, manufacturers, and individuals participate in the program.

7. Identify the harm resulting from the behavior that the proposed rules are designed to alter and the likelihood that the harm will occur in the absence of the rule.

The proposed rules modify the prescription drug repository, distribution, and destruction program under the requirements of the Code. The rules are designed to allow for re-distribution of prescription drug medication to avoid medication waste, diversion, overdoses, and the use of expired drugs. The rules also attempt to avoid discarding prescription drugs by throwing them away with other household waste or allowing them to enter the water system by flushing them when they could be maintained in a closed system and used for patients who may not otherwise be able to afford the medication or discarded in an environmentally conscious process.

A. What is the rationale for changing the rules instead of leaving them as currently written?

The harm that will result from the behavior that the proposed rules are designed to alter will continue in the absence of the proposed rules. The proposed rules clarify concerns with the rules that have been raised by licensees, the department, or the public, which have resulted in previous harm to the public.

8. Describe how the proposed rules protect the health, safety, and welfare of Michigan citizens while promoting a regulatory environment in Michigan that is the least burdensome alternative for those required to comply.

The proposed rules establish, implement, and administer the requirements of the program for the utilization of unused prescription drugs required by the Code. The rules permit the re-distribution of unused medication from a closed system to an eligible patient who may not otherwise be able to afford the medications. Since participation in the program is voluntary, the rules provide for the minimum amount of regulation necessary to ensure the integrity and safe dispensing of the donated medications and to ensure the patient has given informed consent for the acceptance of donated medications.

The Code also requires participating pharmacies and charitable clinics to collect and destroy ineligible prescriptions, as permitted by federal law. The rules provide for the safe and environmentally conscious destruction of medications and prevent diversion, overdoses, and the use of expired medications. Since participation in the program is voluntary, the rules are designed to provide the minimum amount of regulation necessary to ensure for safe collection and disposal of medication while comporting with federal standards.

Promulgation of rules related to the donation, utilization, or destruction of unused prescription drugs is required by statute. The proposed rules will protect the welfare of Michigan citizens by providing greater clarity to the process of donation, utilization, or destruction of unused prescription drugs while reducing waste, lessening environmental concerns, and reducing diversion of drugs.

9. Describe any rules in the affected rule set that are obsolete or unnecessary and can be rescinded.

R 338.3613 is being rescinded as the guardian or medical institution may donate unused drugs without a form.

R 338.3619 is being rescinded as the record keeping requirements are being moved to the form requirements in R 338.3621.

R 338.3623 is being rescinded as the requirements for each form are being modified and placed into separate rules, numbered R 338.3621 through R 338.3621d.

Fiscal Impact on the Agency

Fiscal impact is an increase or decrease in expenditures from the current level of expenditures, i.e. hiring additional staff, higher contract costs, programming costs, changes in reimbursements rates, etc. over and above what is currently expended for that function. It does not include more intangible costs for benefits, such as opportunity costs, the value of time saved or lost, etc., unless those issues result in a measurable impact on expenditures.

10. Please provide the fiscal impact on the agency (an estimate of the cost of rule imposition or potential savings for the agency promulgating the rule).

The department does not expect the implementation of the proposed rules to result in additional costs or savings for the department.

11. Describe whether or not an agency appropriation has been made or a funding source provided for any expenditures associated with the proposed rules.

The implementation and administration of the program for the utilization of unused prescription drugs including the promulgation and implementation of the rules, is funded by the collection of licensing fees. As a result, there was no reason to make an agency appropriation or provide a funding source. Also, the department does not expect the proposed rules to increase expenditures.

12. Describe how the proposed rules are necessary and suitable to accomplish their purpose, in relationship to the burden(s) the rules place on individuals. Burdens may include fiscal or administrative burdens, or duplicative acts.

The rules are required by statute to provide the program for the utilization of unused prescription drugs. The rules are not any more restrictive than is allowed by statute. Despite the cost-related burden, the rules are necessary. There is no expectation of additional burdens, fiscal, administrative, or duplicative acts, on individuals. The proposed rules reduce the burdens on participants by reducing the number of forms and the amount of record keeping.

A. Despite the identified burden(s), identify how the requirements in the rules are still needed and reasonable compared to the burdens.

No additional burdens have been identified. The rules are required by statute to provide the program for the utilization of unused prescription drugs. The rules are not any more restrictive than is allowed by statute.

Impact on Other State or Local Governmental Units

13. Estimate any increase or decrease in revenues to other state or local governmental units (i.e. cities, counties, school districts) as a result of the rule. Estimate the cost increases or reductions for other state or local governmental units (i.e. cities, counties, school districts) as a result of the rule. Include the cost of equipment, supplies, labor, and increased administrative costs in both the initial imposition of the rule and any ongoing monitoring.

The authorizing statute provides that an eligible participant is an individual eligible to receive Medicare, Medicaid, does not have health insurance, or does not have the reasonable means to purchase prescription drugs. R 338.3627 provides that a participating pharmacy or charitable clinic shall not be reimbursed for prescription drugs dispensed through the program but may charge a handling fee. Therefore, the state Medicaid agency may experience savings in prescription drug reimbursement costs. However, participation in the program is voluntary for participants as well as a pharmacies and charitable clinics. Any savings would be dependent upon the level of participation and the quantity and type of drugs donated and dispensed through the program.

If a county medical care facility chose to participate in the program, the facility would incur administrative costs and transportation costs for transferring the donated drugs to the participating pharmacy or charitable clinic.

There are no other anticipated increases or decreases in revenues or costs to other state or local government units because of the proposed rules.

14. Discuss any program, service, duty, or responsibility imposed upon any city, county, town, village, or school district by the rules.

There are no anticipated or intended programs, services, duties, or responsibilities imposed on any city, county, town, village, or school district because of these proposed rules.

A. Describe any actions that governmental units must take to be in compliance with the rules. This section should include items such as record keeping and reporting requirements or changing operational practices.

There are no actions that governmental units must take to comply with the proposed rules.

15. Describe whether or not an appropriation to state or local governmental units has been made or a funding source provided for any additional expenditures associated with the proposed rules.

No appropriations have been made to any governmental units because of these rules. No additional expenditures are anticipated or intended with the proposed rules.

Rural Impact

16. In general, what impact will the rules have on rural areas?

The proposed rules are not expected to impact rural areas. The proposed rules apply to program participants regardless of their location, however, with the changes to the rules more pharmacies, charitable clinics, medical institutions, manufacturers, and individuals who live in rural areas may choose to participate in the program. Eligible and low-income citizens in both rural and urban areas may be able to obtain prescription drugs that they may not otherwise be able to afford.

A. Describe the types of public or private interests in rural areas that will be affected by the rules.

The proposed rules are not expected to impact rural areas. The proposed rules apply to pharmacies, charitable clinics, medical institutions, manufacturers, and individuals who participate in the program regardless of their location.

Environmental Impact

17. Do the proposed rules have any impact on the environment? If yes, please explain.

R 338.3633 requires participating pharmacies or charitable clinic to accept ineligible prescriptions for destruction. The destruction of the ineligible medication shall be in accordance with state and federal standards. As a result, dependent on the number of participating pharmacies and charitable clinics, there will be a greater opportunity for the public to safely dispose of unused medications. The safe disposal of unused medications protects the environment, including the water supply.

Small Business Impact Statement

18. Describe whether and how the agency considered exempting small businesses from the proposed rules.

Participation in the program for the utilization of unused prescription drugs is voluntary. The proposed rules are to ensure for the public health, safety, and welfare in the redistribution and collection of unused prescription medication; the rules are not to regulate business. Therefore, small businesses that choose to participate are not exempt from complying with the rules.

19. If small businesses are not exempt, describe (a) the manner in which the agency reduced the economic impact of the proposed rules on small businesses, including a detailed recitation of the efforts of the agency to comply with the mandate to reduce the disproportionate impact of the rules upon small businesses as described below (in accordance with MCL 24.240(1)(a-d)), or (b) the reasons such a reduction was not lawful or feasible.

Participation in the program for the utilization of unused prescription drugs is voluntary. If a drug manufacturer, medical institution, or participating pharmacy that meets the definition of "small business" chooses to participate, the small business would be subject to the same rules as participants that are not small businesses. The rules are not meant to regulate business but to ensure for the protection of the public health, safety, and welfare in the redistribution and collection of unused prescription medication.

A. Identify and estimate the number of small businesses affected by the proposed rules and the probable effect on small businesses.

Participation in the program for the utilization of unused prescription drugs is voluntary. If a drug manufacturer, medical institution, or pharmacy that meets the definition of "small business" participates in the program, they would be expected to comply with record keeping requirements. Additionally, participating pharmacies would be required to ensure for adequate space for donated inventory and collection devices. Small businesses choosing to participate in the program would be responsible for all costs. In return, participating small businesses may qualify for tax credits/deduction and obtain the good will of a community.

There are approximately 3,540 pharmacies and 559 manufacturers that could participate in the program, which may be considered small businesses depending on their size and annual sales.

The department does not collect or have access to information that would allow it to identify and estimate the number of pharmacies, medical institutions, or manufacturers in Michigan that are small businesses.

B. Describe how the agency established differing compliance or reporting requirements or timetables for small businesses under the rules after projecting the required reporting, record-keeping, and other administrative costs.

The agency did not establish separate compliance or reporting requirements for small businesses. The rules were drafted to be the least burdensome on all affected licensees.

C. Describe how the agency consolidated or simplified the compliance and reporting requirements for small businesses and identify the skills necessary to comply with the reporting requirements.

Participation in the program is voluntary. Therefore, compliance requirements are as minimal as possible to encourage participation while still protecting for the public health, safety, and welfare.

The agency did not consolidate or simplify compliance and reporting requirements with the proposed rules for small businesses. However, the proposed rules have simplified the compliance requirements regarding forms and record keeping for all participants.

D. Describe how the agency established performance standards to replace design or operation standards required by the proposed rules.

Participation in the program is voluntary. Therefore, the department has not established any performance standards to replace design or operation standards required by these rules. The only design standard is R 338.3635, which sets forth the requirements for collection devices. The design standard sets forth the minimum requirements to ensure for tamper resistance and the confidential collection of unused prescription medication.

20. Identify any disproportionate impact the proposed rules may have on small businesses because of their size or geographic location.

Participation in the program is voluntary. The proposed rules will not have a disproportionate impact on small businesses because of their size or geographic location.

21. Identify the nature of any report and the estimated cost of its preparation by small businesses required to comply with the proposed rules.

Participation in the program for the utilization of unused prescription medication is voluntary. However, a drug manufacturer, medical institution, or participating pharmacy satisfying the definition of “small business” that chose to participate would be required to comply with minimal record keeping requirements.

Medical institutions or manufacturers that donate unused prescription medications would be required to complete donation and transfer forms. The records must be kept for a minimum of five years.

Participating pharmacies are required to document information about each donated prescription; maintain a destruction record for abandoned controlled substances and other donations ineligible for re-distribution; create and maintain a destruction record for ineligible prescriptions from collection devices; complete and maintain participating patient forms, and any other pharmacy record required by state or federal law, rules, or regulations. The records must be kept for a minimum period of five years. However, two years after the record is made, the holder of the record may make an electronic duplicate of the original record that becomes the original record.

The estimated cost of the reports will vary depending upon the level of participation. However, the costs are expected to be negligible since the required records closely relate to records required by the practice of pharmacy.

There is no separate cost for report preparation specific to small businesses.

22. Analyze the costs of compliance for all small businesses affected by the proposed rules, including costs of equipment, supplies, labor, and increased administrative costs.

Participation in the program for the utilization of unused prescription medication is voluntary. However, a drug manufacturer, medical institution, or participating pharmacy satisfying the definition of “small business” that chose to participate would incur the following costs:

Drug Manufacturer or Medical Institution

Drug manufacturers and medical institutions may donate used or donated prescription drugs to a participating pharmacy or charitable clinic. To donate, the medical institution must complete a medical institution donation form to be transmitted with the donated drugs. The forms must be reviewed by the pharmacist or authorized healthcare provider and the forms must be retained for a minimum period of five years. Two years after the record is made, the holder of the record may make an electronic duplicate of the original record that becomes the original record. The total time required by the pharmacist would be dependent upon the amount and frequency of donations. The cost for record keeping is estimated to be negligible. Additionally, the drug manufacturer or medical institution will incur shipping costs for a common or contract carrier for transporting the donated drugs to the participating pharmacy or charitable clinic.

Participating Pharmacies

Participating pharmacies are required to inspect the donated prescription drugs, sign the transfer form, and document information for each drug accepted into the program. If a participating pharmacy chooses to transfer the donated prescriptions to a different participating pharmacy or charitable clinic, a pharmacist must complete a transfer form. If dispensing to an eligible participant, the pharmacist must sign the eligible participant form. Additionally, two authorized personnel, one of which must be a pharmacist, shall access collection devices for ineligible prescription medications for destruction. The pharmacist must complete a destruction log. The pharmacist must also destroy the medication on site or complete a destruction log for transfer for destruction. Finally, since donated prescription drugs are to be kept separate from inventory, appropriate space would need to be cleared or created. The total amount of time required by staff would be dependent on the amount and frequency of donated drugs received as well as the number of patients participating in the program. The cost of record keeping is estimated to be negligible since it is closely matches required pharmacy record keeping practices.

Participating pharmacies are required to accept unused prescription drugs from the public for destruction. Collection of unused drugs will require the proper collection equipment. The size of the collection device may be prohibitive from some pharmacies that are limited on space. The cost of destruction of these ineligible prescriptions varies depending on the frequency, size and method of collection. A participating pharmacy with the appropriate resources may be able to perform on-site destruction of the ineligible prescription drugs for minimal costs.

23. Identify the nature and estimated cost of any legal, consulting, or accounting services that small businesses would incur in complying with the proposed rules.

There are no expected increased costs for small businesses concerning legal, consulting, or accounting services.

24. Estimate the ability of small businesses to absorb the costs without suffering economic harm and without adversely affecting competition in the marketplace.

Since participation in the program is voluntary, small business are not required to participate.

25. Estimate the cost, if any, to the agency of administering or enforcing a rule that exempts or sets lesser standards for compliance by small businesses.

Exempting or setting lesser standards of compliance small businesses is not in the best interest of the public and would increase the cost of protecting the public.

26. Identify the impact on the public interest of exempting or setting lesser standards of compliance for small businesses.

Despite the cost-related burdens of the proposed rules, the rules and regulations are necessary to protect the public and are required by statute. Exempting or setting lesser standards of compliance for small businesses is not in the best interest of the public.

27. Describe whether and how the agency has involved small businesses in the development of the proposed rules.

The department worked with multiple stakeholders at the board rules committee work group meetings, which included members from the board, businesses, and other members of the public in the development of the proposed rules. The board is composed of members of the profession and public members who work in businesses in Michigan.

A. If small businesses were involved in the development of the rules, please identify the business(es).

Representatives from businesses were involved in the development of the rules. However, the department is not aware if they meet the definition of a “small business.”

Cost-Benefit Analysis of Rules (independent of statutory impact)

28. Estimate the actual statewide compliance costs of the rule amendments on businesses or groups.

Participation in the program for the utilization for unused prescription medication is voluntary. However, a drug manufacturer, charitable clinic, medical institution, or participating pharmacy that chose to participate would be required to comply with minimal record keeping requirements.

The estimated cost of the report and forms will vary depending upon the level of participation. However, the costs are expected to be negligible.

The total time required by the pharmacist would be dependent upon the amount and frequency of donations. The cost for record keeping is estimated to be negligible. Additionally, the drug manufacturer or medical institution will incur shipping costs for a common or contract carrier for transporting the donated drugs to the participating pharmacy or charitable clinic, which will depend on their level of involvement in the program.

The total amount of time required by pharmacy staff would be dependent on the amount and frequency of donated drugs received as well as the number of patients participating in the program. The cost of record keeping is estimated to be negligible since it is closely matches required pharmacy record keeping practices.

Participating pharmacies are required to accept unused prescription drugs from the public for destruction. Collection of unused drugs will require the proper collection equipment. The size of the collection device may be prohibitive from some pharmacies that are limited on space. The cost of destruction of these ineligible prescriptions varies depending on the frequency, size, and method of collection. A participating pharmacy with the appropriate resources may be able to perform on-site destruction of the ineligible prescription drugs for minimal costs.

A. Identify the businesses or groups who will be directly affected by, bear the cost of, or directly benefit from the proposed rules.

Participation in the program for the utilization for unused prescription medication is voluntary.

Participating drug manufacturers, charitable clinics, medical institutions, and pharmacies will be affected by, and bear the cost of the proposed rules.

The authorizing statute provides that an eligible participant is an individual eligible to receive Medicare, Medicaid, does not have health insurance, or does not have reasonable means to purchase prescription drugs. R 338.3627 provides that a participating pharmacy or charitable clinic shall not be reimbursed for prescription drugs dispensed through the program but may charge a handling fee. Therefore, the state Medicaid agency may experience savings in prescription drug reimbursement costs. However, participation in the program is voluntary for participants as well as pharmacies and charitable clinics. Any savings would be dependent upon the level of participation and the quantity and type of drugs donated and dispensed through the program.

If a county medical care facility chose to participate in the program, the facility would incur administrative costs and transportation costs for transferring the donated drugs to the participating pharmacy or charitable clinic.

B. What additional costs will be imposed on businesses and other groups as a result of these proposed rules (i.e. new equipment, supplies, labor, accounting, or recordkeeping)? Please identify the types and number of businesses and groups. Be sure to quantify how each entity will be affected.

Participation in the program for the utilization for unused prescription medication is voluntary. However, a drug manufacturer, charitable clinic, medical institution, or participating pharmacy that chose to participate would be required to comply with minimal record keeping requirements.

The estimated cost of the report and forms will vary depending upon the level of participation. However, the costs are expected to be negligible.

The total time required by the pharmacist would be dependent upon the amount and frequency of donations. The cost for record keeping is estimated to be negligible. Additionally, the drug manufacturer or medical institution will incur shipping costs for a common or contract carrier for transporting the donated drugs to the participating pharmacy or charitable clinic, which will depend on their level of involvement in the program.

The total amount of time required by pharmacy staff would be dependent on the amount and frequency of donated drugs received as well as the number of patients participating in the program. The cost of record keeping is estimated to be negligible since it is closely matches required pharmacy record keeping practices.

Participating pharmacies are required to accept unused prescription drugs from the public for destruction. Collection of unused drugs will require the proper collection equipment. The size of the collection device may be prohibitive from some pharmacies that are limited on space. The cost of destruction of these ineligible prescriptions varies depending on the frequency, size and method of collection. A participating pharmacy with the appropriate resources may be able to perform on-site destruction of the ineligible prescription drugs for minimal costs.

The department does not expect the proposed rules to result in any other additional costs other than those described above.

29. Estimate the actual statewide compliance costs of the proposed rules on individuals (regulated individuals or the public). Include the costs of education, training, application fees, examination fees, license fees, new equipment, supplies, labor, accounting, or recordkeeping.

Participation in the program for the utilization for unused prescription medication is voluntary.

If an eligible pharmacy or charitable clinic chose to participate, the costs to individual pharmacists are described above in Question #28.

There are no associated costs for eligible participants to participate in the program.

A. How many and what category of individuals will be affected by the rules?

There are 17,266 pharmacists, 25,415 pharmacy technicians, and 1,714 pharmacy interns in Michigan. Pharmacists, pharmacy staff, and the public will be affected by the rules, but the department does not expect any additional costs to these individuals.

B. What qualitative and quantitative impact do the proposed changes in rules have on these individuals?

Participation in the program for the utilization for unused prescription medication is voluntary.

Eligible and low-income citizens may be able to obtain prescription drugs from a closed system that they may not otherwise be able to afford.

The rules provide for the safe and environmentally conscious destruction of medications. The rules also prevent diversion, overdoses, and the use of expired medications.

30. Quantify any cost reductions to businesses, individuals, groups of individuals, or governmental units as a result of the proposed rules.

The Medicare and Medicaid Agencies may experience savings related to prescription claim reimbursements. The amount of savings would be dependent on the number of enrolled beneficiaries that participated in the program and if a participating pharmacy or charitable clinic had the prescribed donated medication to dispense. The savings would also depend on the type and quantity of the prescription medication dispensed to participating beneficiaries by the participating pharmacy or charitable clinic.

Although negligible, the proposed changes to forms and record retention may also reduce costs to all participants.

31. Estimate the primary and direct benefits and any secondary or indirect benefits of the proposed rules. Please provide both quantitative and qualitative information, as well as your assumptions.

Primary benefits

The proposed rules implement and administer a program which utilizes safe, unused prescription medications and distributes these prescription medications to low-income patients who may not otherwise be able to afford the medications. The proposed rules also provide for the collection of ineligible prescription medication for disposal and destruction, preventing diversion, overdose, and consumption of expired drugs as well as environmental protection.

Although negligible, the proposed changes to forms and record retention is also a benefit to participants.

Secondary benefits

The proposed rules may provide savings for county health care facilities and the Medicare and Medicaid programs. The savings for the Medicare and Medicaid agencies would arise from decreased prescription reimbursements if enough beneficiaries participated in the program and the participating pharmacy or charitable clinic had obtained eligible donated medications for dispensing to these participating beneficiaries. The savings would also depend on the type and quantity of the prescription medication dispensed to participating beneficiaries by the participating pharmacy or charitable clinic.

The public benefits from every substantive change in the proposed rules as all changes have been proposed to protect the public.

32. Explain how the proposed rules will impact business growth and job creation (or elimination) in Michigan.

The rules are not expected to have an impact on business growth, job creation, or job elimination.

33. Identify any individuals or businesses who will be disproportionately affected by the rules as a result of their industrial sector, segment of the public, business size, or geographic location.

There is not expected to be a disproportionate effect due to industrial sector, segment of the public, business size, or geographic location.

34. Identify the sources the agency relied upon in compiling the regulatory impact statement, including the methodology utilized in determining the existence and extent of the impact of the proposed rules and a cost-benefit analysis of the proposed rules.

Michigan Public Health Code, MCL 333.1101 et seq.

State Prescription Drug Repository Programs (ncsl.org)

<https://www.fda.gov/drugs/disposal-unused-medicines-what-you-should-know/drug-disposal-drug-take-back-locations>

<https://www.getsmartaboutdrugs.gov/gsad/national-take-back-day>

Can Unused Prescription Drugs Be Donated? | What You Need to Know (therecoveryvillage.com)

<https://www.dea.gov/press-releases/2014/09/08/dea-releases-new-rules-create-convenient-safe-and-secure-prescription>

<https://sirum.org/>

<https://www.michigan.gov/lara/-/media/Project/Websites/lara/bpl/Shared-Files/BPL-Active-License-Counts.pdf?rev=7210aa39fba04c1895702b60c49a9f06>

<https://www.congress.gov/112/plaws/publ273/PLAW-112publ273.pdf>

https://www.deadiversion.usdoj.gov/faq/disp_destr_faq.htm

<https://www.congress.gov/111/plaws/publ273/PLAW-111publ273.pdf>

<https://www.govinfo.gov/content/pkg/FR-2014-09-09/pdf/2014-20926.pdf>

<https://www.ecfr.gov/current/title-21/chapter-II/part-1317>

2023 Survey of Pharmacy Law, NABP

The National Association of Boards of Pharmacy, (Resolution 116-4-20), June 3, 2020.

<https://nabp.pharmacy/news/news-releases/task-force-on-medication-reuse/>

The National Association of Boards of Pharmacy, Report of the Task Force on Medication Reuse

A. How were estimates made, and what were your assumptions? Include internal and external sources, published reports, information provided by associations or organizations, etc., that demonstrate a need for the proposed rules.

No estimates or assumptions were made.

Alternative to Regulation

35. Identify any reasonable alternatives to the proposed rules that would achieve the same or similar goals.

There are no other reasonable alternatives to the proposed rules that would achieve the same or similar goals except to modify the Code. The Code requires the department in consultation with the board to establish and implement by rule and administer a statewide unused prescription drug repository and distribution program. The program shall allow unused or donated prescription drugs, other than controlled substances, to be transferred from a medical institution or manufacturer to a pharmacy or charitable clinic that elects to participate in the program. In addition, the Code requires that subject to rules, the program accept medications that are ineligible for distribution, which shall be destroyed and disposed of.

A. Please include any statutory amendments that may be necessary to achieve such alternatives.

Eliminate the Code provisions that require rules to establish, implement, and administer a statewide program.

36. Discuss the feasibility of establishing a regulatory program similar to that proposed in the rules that would operate through private market-based mechanisms. Please include a discussion of private market-based systems utilized by other states.

Under the Code, the department and the board are responsible for establishing, implementing, and administering the program for the utilization of unused prescription drugs. Therefore, it is not feasible to establish a regulatory program that would operate through private market-based mechanisms.

37. Discuss all significant alternatives the agency considered during rule development and why they were not incorporated into the rules. This section should include ideas considered both during internal discussions and discussions with stakeholders, affected parties, or advisory groups.

No alternatives were considered during rule development.

Additional Information

38. As required by MCL 24.245b(1)(c), please describe any instructions regarding the method of complying with the rules, if applicable.

The rules will explicitly inform applicants of the eligibility requirements, how to apply as a participant in the program, the necessary forms, and the record retention requirements.